Xilio Therapeutics, Inc.
XLO
$8.46
-$0.05-0.59%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -28.22% | 135.85% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -28.22% | 135.85% | |||
| Cost of Revenue | -364.77% | -6.58% | |||
| Gross Profit | 987.52% | 165.48% | |||
| SG&A Expenses | 10.88% | -6.26% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 21.56% | -6.48% | |||
| Operating Income | -513.58% | 86.57% | |||
| Income Before Tax | 163.61% | -2.80% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 163.61% | -2.80% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 163.61% | -2.80% | |||
| EBIT | -513.58% | 86.57% | |||
| EBITDA | -624.54% | 88.64% | |||
| EPS Basic | 121.73% | -2.79% | |||
| Normalized Basic EPS | 121.73% | -2.79% | |||
| EPS Diluted | 121.73% | -2.79% | |||
| Normalized Diluted EPS | 121.73% | -2.79% | |||
| Average Basic Shares Outstanding | 192.71% | 0.00% | |||
| Average Diluted Shares Outstanding | 192.71% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||